AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 11.8% in January

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totalling 882,000 shares, a decline of 11.8% from the December 31st total of 1,000,000 shares. Based on an average daily volume of 625,200 shares, the days-to-cover ratio is presently 1.4 days.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Canaccord Genuity Group lowered their target price on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th. HC Wainwright upped their target price on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 10th.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its position in shares of AngioDynamics by 110.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock valued at $1,240,000 after purchasing an additional 83,622 shares during the last quarter. State Street Corp increased its position in shares of AngioDynamics by 2.7% during the 3rd quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock valued at $6,305,000 after purchasing an additional 21,218 shares during the last quarter. Barclays PLC increased its position in shares of AngioDynamics by 81.0% during the 3rd quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock valued at $651,000 after purchasing an additional 37,394 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of AngioDynamics by 28.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock valued at $4,304,000 after purchasing an additional 123,271 shares during the last quarter. Finally, CWM LLC increased its position in shares of AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after purchasing an additional 8,832 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO traded down $0.75 during trading on Friday, reaching $11.72. 925,398 shares of the stock were exchanged, compared to its average volume of 1,068,643. The firm has a market cap of $474.11 million, a price-to-earnings ratio of -2.08 and a beta of 0.59. The stock has a fifty day moving average of $9.61 and a two-hundred day moving average of $8.03. AngioDynamics has a 1-year low of $5.26 and a 1-year high of $13.50.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. AngioDynamics’s quarterly revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.05) EPS. Sell-side analysts forecast that AngioDynamics will post -0.37 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.